- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07948317
Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial
A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).
The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes.
Participants will be randomly assigned in a 1:1 ratio to one of two groups:
Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy.
Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy.
After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin.
The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Background:
Head and neck squamous cell carcinoma (HNSCC) is a common malignancy worldwide. For locally advanced resectable HNSCC, the standard treatment paradigm often involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. However, the 5-year survival rate remains suboptimal, and the optimal neoadjuvant regimen is still debated. Immunotherapy, particularly PD-1 inhibitors, has shown promising efficacy in recurrent/metastatic HNSCC. Our previous Phase II trial demonstrated that neoadjuvant Camrelizumab combined with nab-paclitaxel and cisplatin was safe and highly effective (Objective Response Rate of 89.6%). This Phase III study is designed to further validate these findings.
Study Design:
This is a randomized, open-label, multicenter, Phase III clinical trial. A total of 212 eligible patients with clinical stage III-IV (T2N2-3M0, T3-4N0-3M0, AJCC 8th) resectable HNSCC will be enrolled and randomized 1:1 to the experimental or control group.
Interventions:
Experimental Arm: Neoadjuvant Camrelizumab (200 mg, IV, Day 1) + nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles (21-day cycle).
Control Arm: Neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles.
After 3 cycles, tumor response will be evaluated per RECIST v1.1. Patients with oropharyngeal, laryngeal, or hypopharyngeal cancer who achieve CR/PR and wish to preserve organ function will receive radical radiotherapy plus cisplatin; those with residual disease will undergo salvage surgery. Other patients will undergo radical surgery with organ preservation. Adjuvant therapy will be administered based on NCCN/CSCO guidelines and multidisciplinary team discussion.
Outcomes:
The primary endpoint is 2-year Event-Free Survival (EFS). Secondary endpoints include 2-year Overall Survival (OS), 2-year Progression-Free Survival (PFS), organ preservation rate, Disease Control Rate (DCR), Objective Response Rate (ORR), safety, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and exploratory biomarker analysis (PD-L1 CPS, TMB, etc.).
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Xuekui Liu, MD, PhD
- Telefonnummer: 020-87343009
- E-post: liuxuek@sysucc.org.cn
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
1. Histologically and/or cytologically confirmed, previously untreated head and neck squamous cell carcinoma (diagnostic treatment excluded).
2. Clinical stage T2N2-3M0 or T3-4N0-3M0 (Stage III-IV, AJCC 8th edition). 3. Age between 18 and 70 years. 4. ECOG Performance Status (PS) of 0 or 1. 5. Assessed by a head and neck oncologist as resectable with no distant metastasis.
6. At least one evaluable lesion according to RECIST v1.1. 7. Adequate organ function to tolerate surgery:
-
Hematology: WBC ≥ 4000/μL, ANC ≥ 2.000/μL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100,000/μL.
-
Liver function: Bilirubin ≤ 1.5× ULN, AST/ALT ≤ 3× ULN, ALP ≤ 3× ULN, Albumin ≥ 3 g/dL.
-
Renal function: Serum creatinine ≤ 1.5× ULN or Cockcroft-Gault creatinine clearance ≥ 60 mL/min.
8. Signed informed consent and willingness to comply with study procedures.
Exclusion Criteria:
-
1. History of severe hypersensitivity to other monoclonal antibodies or any component of PD-1 monoclonal antibodies.
2. Known or suspected autoimmune diseases, including dementia and epilepsy. 3. Recurrent disease, distant metastasis, concurrent other malignancies, or assessed as unresectable.
4. Coagulation abnormalities (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency, or receiving thrombolytic/anticoagulant therapy.
5. Severe heart or lung disease; cardiac or pulmonary function below grade 3 (including grade 3).
6. Laboratory test values within 7 days prior to enrollment not meeting the relevant standards.
7. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibody targeting T-cell co-stimulation or checkpoint pathways).
8. Comorbidities requiring long-term immunosuppressive therapy or systemic/local use of immunosuppressive doses of corticosteroids prior to enrollment.
9. HIV positive; HBsAg positive with detectable HBV DNA (≥ 1000 cps/ml); positive blood screening for chronic hepatitis C (HCV antibody positive).
10. Use of anti-tumor traditional Chinese herbal medicine within 4 weeks prior to randomization.
11. Pregnant or lactating women.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Camrelizumab plus Chemotherapy
Patients receive neoadjuvant Camrelizumab (200 mg, IV, Day 1) combined with nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response. |
Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.
Andre navn:
Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
Andre navn:
Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
Andre navn:
|
|
Aktiv komparator: Chemotherapy Alone
Patients receive neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response. |
Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
Andre navn:
Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
2-year Event-Free Survival (EFS) Rate
Tidsramme: 2 years from randomization
|
Event-Free Survival (EFS) is defined as the time from randomization to the first occurrence of any of the following events: disease progression that precludes surgery, local or distant recurrence, treatment termination due to toxicity or complications, or death from any cause. The rate at 2 years will be calculated. |
2 years from randomization
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
2-year Overall Survival (OS) Rate
Tidsramme: 2 years from randomization
|
The percentage of patients alive at 2 years from randomization. If the patient died within 2 years, it will be censored at the last known alive date. |
2 years from randomization
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Karsinom
- Karsinom, plateepitel
- Plateepitelkarsinom i hode og nakke
- Neoplasmer i hode og nakke
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Taxoider
- Cyclodecanes
- Diterpenes
- Platinumforbindelser
- Albuminer
- Paclitaxel
- Albuminbundet paklitaksel
- Cisplatin
- 130-nm albuminbundet paclitaxel
- Camrelizumab
Andre studie-ID-numre
- B2024-782
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .